NovoCure Ltd (NVCR) stock
NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3027% below fair value
$11.83+0.11 (+0.94%)
Close on Nov 13, 2026Market cap $1.38BP/E –Yield –
NovoCure enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
NovoCure's enterprise value was $1.29B on Nov 11, 2026, against $1.09B a year earlier. Over the last 5 years it ranged from $1.05B to $9.89B, with a median of $2.00B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.29B | +16.9% |
| 2025 | Dec 31, 2025 | $1.11B | -63.6% |
| 2024 | Dec 31, 2024 | $3.04B | +51.3% |
| 2023 | Dec 29, 2023 | $2.01B | -75.0% |
| 2022 | Dec 30, 2022 | $8.02B | +4.6% |
| 2021 | Dec 31, 2021 | $7.67B | -55.9% |
| 2020 | Dec 31, 2020 | $17.37B | +109.8% |
| 2019 | Dec 31, 2019 | $8.28B | +163.8% |
| 2018 | Dec 31, 2018 | $3.14B | +72.6% |
| 2017 | Dec 29, 2017 | $1.82B | +178.2% |
| 2016 | Dec 30, 2016 | $653.48M | +240.0% |
| 2015 | Dec 31, 2015 | $192.22M | – |
See a number that looks wrong?